BioMarin Pharmaceutical

Alexander Hardy

BioMarin Pharmaceutical has appointed Alexander Hardy as president and chief executive officer. Hardy has over three decades of experience in the global healthcare and biotechnology industries. He most recently served as chief executive officer at Genentech. Prior to this, Hardy held the position of head of global product strategy at Roche, which followed his position as head of Asia, Pacific.

Catalyst Pharmaceuticals

Richard Daly

Catalyst Pharmaceuticals has appointed Richard Daly as chief executive officer. Daly brings over three decades of experience in pharmaceuticals to his new role. He most recently served as president of CARsgen Therapeutics. Prior to this, Daly served as chief operating officer at Beyond Springs, which followed his position as chief executive officer and president of Neuralstem earlier in his career.

Fibrocor Therapeutics

William Newsome

Fibrocor Therapeutics has appointed William Newsome as chief executive officer. Newsome holds over two decades of experience in the pharmaceutical industry. He was one of the co-founders of Fibrocor and has remained involved with the company as a non-executive director. Newsome has also served in several positions at Evotec, including senior vice president and US head, strategic alliance and partnership management.

Genascence

Ian Lachlan McLean

Genascence has appointed Ian Lachlan McLean as chief medical officer. McLean holds over two decades of extensive experience in clinical research and development in the biopharmaceutical industry. He most recently served as chief medical officer at Novome Biotechnologies. Prior to this, McLean spent nearly a decade at Takeda Pharmaceuticals in a variety of positions, including vice president and head of immunology.

Bristol Myers Squibb

Christopher Boerner

Bristol Myers Squibb has appointed Christopher Boerner as chair of the board of directors. Over nearly a decade, Boerner has served in several senior positions at the company. He currently serves as chief executive officer, following his roles as executive vice president and chief operating officer. Prior to this, Boerner served as executive vice president, commercial, at Seattle Genetics.

Biogen

Monish Patolawala

Biogen has appointed Monish Patolawala to its board of directors. Patolawala has nearly three decades of experience in financial operations and global industrial and healthcare businesses. He currently serves as president and chief financial officer at 3M Company. Prior to this, he served in a variety of roles at General Electric Company (GE), including chief financial officer of GE Healthcare.

IO Biotech

Helen Collins

IO Biotech has appointed Helen Collins to its board of directors. Collins brings nearly three decades of medical experience to her new position and currently serves as chief medical officer at Enliven Therapeutics. Prior to this, she served as chief medical officer and executive vice president at Five Prime Therapeutics. Collins also held positions at Gilead Sciences and Amgen.

LifeArc

Roger Barker

LifeArc has appointed Roger Barker as chair of its neurodegeneration efforts. Barker is professor of clinical neuroscience at the University of Cambridge and consultant neurologist at Addenbrooke’s Hospital. He also leads the regional NHS Huntington’s disease and an NHS Parkinson’s disease clinic, and serves as the lead academic scientist of the Alzheimer’s Research UK-funded Drug Discovery Institute in Cambridge.

Chiesi

David Garzón Lafuente

Chiesi has appointed David Garzón Lafuente as rare disease business unit lead. Lafuente carries nearly two decades of experience in the pharmaceutical industry. He has previously held several senior positions within the Chiesi group and most recently served as business unit head of rare diseases for Chiesi Spain and Portugal. Lafuente currently serves as general manager, Iberia and Israel at Amryt Pharma.

Galimedix Therapeutics

Luciana Summo

Galimedix Therapeutics has appointed Luciana Summo as vice president, research and development operations. Summo brings over two decades of experience in clinical development and operations to her new position. She most recently served as director of clinical operations at OMEICOS Therapeutics. Prior to this, Summo served at Berlin-Chemie for nearly a decade, most recently as clinical study manager.

Poolbeg Pharma

Laura Maher

Poolbeg Pharma has appointed Laura Maher as vice president of clinical operations. Maher brings nearly two decades of extensive experience in clinical operations. She most recently served as associate director of clinical operations at Amryt. Maher also served in a variety of roles at Prothena Biosciences, Cancer Trials Ireland and the European Organisation for Research and Treatment of Cancer.

Fibrocor Therapeutics

Piet Wigerinck

Fibrocor Therapeutics has appointed Piet Wigerinck as chief scientific advisor. Wigerinck has over two decades of experience and has held several senior positions. He currently serves as chief scientific officer at Galapagos, which followed his position as senior vice president of development. Wigerinck also served as vice president of medicinal chemistry at Tibotec and head of the research lab, medicinal chemistry at Janssen Research Foundation.

Macomics

Kevin Lee

Macomics has appointed Kevin Lee as independent non-executive director. Lee brings two decades of biotech and pharma experience to his new position. In addition to his new role, he currently serves on the Bicycle Therapeutics board of directors and is non-executive director of Alchemab Therapeutics. Lee has also served as senior vice president and chief scientific officer, rare disease research unit at Pfizer.

NanoSyrinx

Anthony Johnson

NanoSyrinx has appointed Anthony Johnson as non-executive director. Johnson has over two decades of experience in senior and executive positions for early-stage biotech and pharma companies. Most recently, he served as chief executive officer at Goldfinch Bio and is currently chair of the board of directors at Outrun Therapeutics. Prior to this, he served in senior positions at AstraZeneca, Bristol Myers Squibb and GSK.

Scorpion Therapeutics

Jeff Albers

Scorpion Therapeutics has appointed Jeff Albers as strategic advisor. Albers has over two decades of in-depth biopharmaceutical industry experience, particularly in areas including rare diseases and cancer. Albers previously served as chief executive officer of Blueprint Medicines. He currently serves as the chairman of Blueprint, MOMA Therapeutics and Pheon Therapeutics.

Invizius

Bernard Canaud

Invizius has appointed Bernard Canaud to its clinical advisory board. Canaud brings over four decades of experience to his new position. He currently serves as emeritus professor of nephrology at the Montpellier University School of Medicine in France. Prior to this, he served as chief medical officer for Fresenius Medical Care’s Europe, Middle East, Africa and Latin America division.

Envision Pharma Group

Loubna Bouarfa

Envision Pharma Group has appointed Loubna Bouarfa as AI thought leader and chairwoman of its newly established board. Bouarfa was previously the chief executive officer and founder of OKRA.AI, a high-level expert of AI for the European Commission and a global advisor at Mosaic Research Management. She also currently serves as member of the board of advisors at Oxford Internet Institute.

Porterhouse Medical

Danielle Frodyma

Porterhouse Medical has appointed Danielle Frodyma as senior medical writer. Frodyma brings a wealth of medical communications experience across a range of therapeutic areas, including breast cancer and haematological malignancies, to her new role. She most recently served as senior medical writer at PharmaHEALTHLabs. Prior to this, she served as a clinical research coordinator at Nebraska Methodist Health System.

Executive Insight

Sabrina Gaid

Executive Insight has appointed Sabrina Gaid as healthcare consultant. Gaid brings a strong background in business and economics to her new position. Most recently, she served as strategy consulting intern at Monitor Deloitte and, prior to this, at ANETO. Earlier in her career, Gaid served as head of business development as part of an internship at Life Bloom Academy.

90TEN

Chloe Dodsworth

90TEN has appointed Chloe Dodsworth as medical writer. Dodsworth brings nearly three years of experience in medical communications to her new position. She most recently served as a medical writer and project coordinator at Bham Pharma. Prior to this, she served as a junior medical writer and project coordinator after completing her internship as a medical writer when she first joined the company.